Haleon halts Centrum OTC imports into China after raw material classification change
HLN•Haleon halted imports of Centrum products registered as over-the-counter medicines into China until further notice after a raw material classification change. The products generated about £75 million in FY 2025 revenue; Haleon now expects FY 2026 organic revenue growth of around 2.5%, including the China disruption and Brazil distribution changes.
1. China import halt
Haleon halted imports into China of Centrum products registered as over-the-counter medicines following a raw material classification change. The affected products generated approximately £75 million in FY 2025 revenue; food-registered Centrum products are unaffected, and the change was unrelated to product quality or safety.
2. Growth outlook revised
Haleon expects FY 2026 organic revenue growth of around 2.5%, incorporating the China disruption and changes to distribution in Brazil. The Brazil rollout will accelerate to coincide with the country’s new tax framework, reducing fourth-quarter net revenue by approximately £15 million to £20 million.
